Ли Ноу - Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость
- Название:Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость
- Автор:
- Жанр:
- Издательство:Питер
- Год:2020
- Город:Санкт-Петербург
- ISBN:978-5-4461-1021-6
- Рейтинг:
- Избранное:Добавить в избранное
-
Отзывы:
-
Ваша оценка:
Ли Ноу - Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость краткое содержание
В нашем организме работают крошечные «энергетические станции» — митохондрии. Именно они отвечают за наше здоровье и отличное самочувствие. Когда они работают хорошо, мы не испытываем недостатка в энергии. А когда плохо — страдаем от заболеваний. Доктор Ли Ноу открывает тайну: заболевания, которые кажутся не связанными между собой на первый взгляд: диабет, рак, шизофрения, хроническая усталость, болезнь Паркинсона и другие — имеют общую природу.
Сегодня нам известно, как улучшить работу митохондрий, обеспечивающих организм энергией на 90 %. В этой книге вас ждет актуальная информация о питании, образе жизни, кетогенной диете и добавках, которые возвращают здоровье митохондриям, а следовательно, и нам.
Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость - читать онлайн бесплатно ознакомительный отрывок
Интервал:
Закладка:
Schon E. A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003 Feb; 111(3):303–12. doi:10.1172/JCI17741. Schulte E. C., et al. Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Mov Disord. 2013 Feb; 28(2):224–7. Epub 2012 Nov 19. doi:10.1002/mds.25256.
Schulz J. B., et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71. 1996; 71(4):1043–48. doi:10.1016/0306-4522(95)00527-7.
Sobreira C, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997 May; 48(5):1238–43.
Sun T., et al. Motile axonal mitochondria contribute to the variability of presynaptic strength. Cell Rep. 2013 Aug 15; 4(3):413–9. Epub 2013 Jul 23. doi:10.1016/j.celrep.2013.06.040.
Tatton W. G., Chalmers-Redman R. M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann Neurol. 1998; 44(3 Suppl 1):S. 134–S. 141. doi:10.1002/ana.410440720.
Tatton W. G, Olanow C. W. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta. 1999 Feb 9; 1410(2):195–213. doi:10.1016/S0005-2728(98)00167-4.
Turner C., Schapira A. H. Mitochondrial dysfunction in neurodegenerative disorders and ageing. Adv Exp Med Biol. 2001; 487:229–51.
Veitch K. et al. Global ischemia induces a biphasic response of the mitochondrial respiratory chain. Anoxic pre-perfusion protects against ischaemic damage. Biochem J. 1992 Feb 1; 281(Pt 3):709–15.
Volpe M., Cosentino F. Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. J Cardiovasc Pharmacol. 2000; 35(4 Suppl 2):S. 45–S. 48.
Berger A. The Alzheimer’s antidote: Using a low-carb, high-fat diet to fight Alzheimer’s disease, memory loss, and cognitive decline. White River Junction, VT: Chelsea Green Publishing, 2017.
Blass J. P. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome. Ann NY Acad Sci. 2000; 924:170–83. doi:10.1111/j.1749–6632.2000.tb05576.x.
Bonilla E., et al. Mitochondrial involvement in Alzheimer’s disease. Biochim Biophys Acta. 1999 Feb 9; 1410(2):171–82. doi:10.1016/S0005-2728(98)00165-0.
Brown A. M., et al. Correlation of the clinical severity of Alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci. 2001 Feb; 16(1):41–8. doi:10.1385 /JMN:16:1:41.
Cavallucci V., Ferraina C., D’Amelio M. Key role of mitochondria in Alzheimer’s disease synaptic dysfunction. Curr Pharm Des. 2013; 19(36):6440–50. Epub 2013 Feb 13.
Chen J. X., Yan S. D. Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis. 2007 Sep; 12(2):177–84. doi:10.3233/JAD-2007-12208.
Duboff B., Feany M., Götz J. Why size matters — balancing mitochondrial dynamics in Alzheimer’s disease. Trends Neurosci. 2013 Jun; 36(6):325–35. Epub 2013 Apr 11. doi:10.1016 /j.tins.2013.03.002.
Gabuzda D., et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994 May 6; 269(18):13623–8.
Harman D. A hypothesis on the pathogenesis of Alzheimer’s disease. Ann NY Acad Sci. 1996 Jun 15;786:152–68. doi:10.1111/j.1749–6632.1996. tb39059.x.
Hu H., et al. A mitocentric view of Alzheimer’s disease. Mol Neurobiol. 2016 Oct 1. Epub ahead of print. doi:10.1007/s12035-016-0117-7.
Lustbader J. W., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004 Apr 16; 304(5669):448–52. doi:10.1126/science.1091230.
Mariani C., et al. Muscle biopsy in Alzheimer’s disease: morphological and biochemical findings. Clin Neuropathol. 1991 Jul; 10(4):171–6.
Mark R. J., et al. Amyloid b-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997 Feb 1; 17(3): 1046–54.
Markesbery W. R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997; 23(1):134–47. doi:10.1016/S0891-5849(96)00629-6. Markesbery W. R. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 1999 Jan; 9(1): 133–46. doi:10.1111/j.1750–3639.1999.tb00215.x. Muller W. E., et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease-therapeutic aspects. Mol Neurobiol. 2010 Jun; 41(2–3):159–71. doi:10.1007/s12035-010-8141-5.
Munch G., et al. Alzheimer’s disease — synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna). 1998; 105(4–5):439–61. doi:10.1007/s007020050069.
Nia S. S., et al. New pathogenic variations of mitochondrial DNA in Alzheimer disease! [letter]. J Res Med Sci. 2013 Mar; 18(3):269.
Nicotera P., Leist M., Manzo L. Neuronal cell death: a demise with different shapes. Trends Pharmacol Sci. 1999 Feb 1; 20(2):46–51. doi:10.1016/ S0165-6147(99)01304-8.
Ogawa M, et al. Altered energy metabolism in Alzheimer’s disease. J Neurol Sci. 1996 Jul; 139(1):78–82. doi:10.1016/0022-510X(96)00033-0.
Sery O., et al. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol. 2013; 51(1):1–9. doi:10.5114/fn.2013.34190.
Smith M. A., et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997 Apr 15; 17(8):2653–7.
Sochocka M., et al. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer’s disease: new approach to therapy. CNS Neurol Disord Drug Targets. 2013 Sep; 12(6):870–81. Epub Feb 27. doi:1 0.2174/18715273113129990072.
Wang X., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci. 2009 Jul 15; 29(28):9090–103. doi:10.1523/ JNEUROSCI.
Webster M. T., et al. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm. 1998 Nov; 105(8–9):839–53. doi:10.1007 /s007020050098.
Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer’s disease. Gerontology. 1997; 43:242–53. doi:10.1159/000213856.
Adeghate E., Donath T., Adem A. Alzheimer disease and diabetes mellitus: do they have anything in common? Curr Alzheimer Res. 2013 Jul; 10(6):609–17. Epub Apr 29. doi:10.2174 /15672050113109990009.
Cetinkalp S., Simsir I. Y., Ertek S. Insulin resistance in brain and possible therapeutic approaches. Curr Vasc Pharmacol. 2014; 12(4):553–64. Epub Apr 25. doi:10.2174/1570161112999140206 130426.
Geda Y. E. Abstract 3431. Paper presented at: American Academy of Neurology (AAN) 64th Annual Meeting; 2012 Apr 21–28; New Orleans, Louisiana. Mastrogiacomo F., Bergeron C., Kish E. J. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. J Neurochem. 1993 Dec; 61(6):2007–14. doi:10.1111/j.1471–4159.1993.tb07436.x.
Abou-Sleiman P. M., Muqit M. M, Wood N. W. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 2006 Mar; 7(3):207–19. doi:10.1038/nrn1868.
Beal M. F. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S189–S194. doi:10.1016/S1353-8020(09) 70812-0.
Beal M. F., et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998 Feb; 783(1):109–14. doi:10.1016/S0006-8993(97)01192-X.
Bender A., et al. TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson’s disease. PLoS One. 2013 Apr 23; 8(4):e62277.
Berndt N., Holzhutter H. G., Bulik S. Implications of enzyme deficiencies on the mitochondrial energy metabolism and ROS formation of neurons involved in rotenone-induced Parkinson’s disease: A model-based analysis. FEBS J. 2013 Sep 12; 280(20):5080–93. Epub 2013 Aug 13. doi:10.1111/ febs.12480.
Dolle C., et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016 Nov 22; 7:13548.
Ebadi M., et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson’s disease. 2001. Biol Signals Recept 10:224–53. doi:10.1038/ncomms13548.
Freeman D., et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One. 2013 Apr 25; 8(4):e62143.
Haas R. H., et al. Low platelet mitochondrial complex I and complex II/ III activity in early untreated Parkinson’s disease. Ann Neurol. 1995 Jun; 37(6):714–22. doi:10.1002/ana.410370604.
Henchcliffe C., Beal M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008 Nov; 4(11):600–9. doi:10.1038/ncpneuro0924.
Hosamani R., Muralidhara. Acute exposure of Drosophila melanogaster to paraquat causes oxidative stress and mitochondrial dysfunction. Arch Insect Biochem Physiol. 2013 May; 83(1):25–40. Epub 2013 Apr 5.
Isobe C., Abe T., Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2’-deoxyguanosine in the cerebrospinal fluid of patients living with Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett. 2010 Jan 18; 469(1):159–63. Epub 2009 Nov 26. Lehmann S., Martins L. M. Insights into mitochondrial quality control pathways and Parkinson’s disease. J Mol Med (Berl). 2013 Jun; 91(6):665– 71. Epub May 4. doi:10.1007/s00109-013-1044-y.
Li D. W., et al. α-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med. 2013 Jul;32(1):108–14. Epub Apr 24. doi:10.3892/ ijmm.2013.1361.
Lin T. K., et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Med J. 2009 Nov — Dec; 32(6):589–99.
Lodi R., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001 May 1; 49(5):590–6. doi:10.1002 /ana.1001.
Mena M. A., et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord. 1992; 7(1):23–31. doi:10.1002/mds.870070105.
Mizuno Y., et al. Role of mitochondria in the etiology and pathogenesis of Parkinson’s disease. Biochima et Biophysica Acta. 1995 May 24; 1271(1):265–74. doi:10.1016/0925-4439 (95)00038-6.
Mizuno Y., et al. Mitochondrial dysfunction in Parkinson’s disease. Ann Neurol. 1998 Sep; 44 (3 Suppl 1):S. 99–S. 109.
Musumeci O., et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001 Apr 10; 56(7):849–55.
Читать дальшеИнтервал:
Закладка:
